News

ADC Therapeutics Secures $60 Million for Growth and Innovation

ADC Therapeutics Secures $60 Million for Growth and Innovation

ADC Therapeutics Secures $60 Million for Growth and Innovation

ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has exciting news to share. The company is embarking on a pivotal journey by securing a $60 million private investment in public equity (PIPE) with institutional investors. Through this pipeline, ADC Therapeutics will sell 11.3 million common shares at $4.00 each, alongside pre-funded warrants for an additional 3.8 million shares at $3.90 per warrant, aiming to enhance its position in the biotech realm.

This initiative is spearheaded by TCGX and involves prominent engagement from Redmile Group and other investors eager to support ADC’s vision. The gross proceeds, estimated at $60 million prior to fees and expenses associated with placement agents, are significant for ADC Therapeutics as it sets strategic growth plans into motion.

The anticipated closure of this PIPE is expected to unfold on a date in the near future, pending customary conditions being met. The net proceeds from this financing round are earmarked for advancing the commercial expansion efforts of ZYNLONTA, ADC's flagship product. This funding will also serve to fortify the company’s balance sheet and cover general operational costs.

Ameet Mallik, CEO of ADC Therapeutics, expressed optimism regarding this financing, stating, "This financing enhances our ability to prepare for and execute the potential relaunch of ZYNLONTA in the future. This also strengthens our financial stability, allowing us to envision sustainable growth long-term. Upcoming data catalysts later this year and in the next several years will be pivotal for us."

The projected net revenues from ZYNLONTA sales are expected to reach approximately $15.8 million for a recent quarter, while the company's cash reserves, including cash equivalents, stood at $234.7 million as of a recent month. Once accounting for the estimated proceeds from the PIPE, the total cash and cash equivalents could soar to around $292.3 million, offering a robust cushion for operations moving ahead.

This securities offering is not a public offering and adheres to regulations under certain provisions of the Securities Act. Notably, the securities being offered will not be registered nor can they be reoffered in the U.S. without an effective registration statement, underscoring the strategic approach ADC Therapeutics is taking in this financing round.

Jefferies has stepped in as the placement agent for the PIPE, while legal expertise is provided by Davis Polk & Wardwell LLP and Homburger AG, ensuring that the company navigates these complexities with seasoned guidance.

Additionally, an updated corporate presentation is now available in the Investor section on their website, providing even deeper insights into the company's positioning and potential.

Understanding ZYNLONTA
ZyNLONTA is an advanced CD19-directed antibody drug conjugate that operates on a unique mechanism. Once attached to a cell expressing CD19, ZYNLONTA is internalized, allowing a potent payload to act destructively at the genetic level, leading to cell cycle arrest and eventual cell death. This innovative treatment option received both FDA and EMA approval for use in adults suffering from relapsed or refractory large B-cell lymphoma, demonstrating the effectiveness of ZYNLONTA across a range of patient cases.

The groundwork laid by this company underscores its dedication to challenging the status quo in oncology and hematologic treatment landscapes. With FDA’s accelerated approval and the ongoing investigations expanding its application in other B-cell malignancies, ZYNLONTA establishes a powerful example of how ADC technology can revolutionize therapy.

About ADC Therapeutics
Based in Biopôle, Switzerland, ADC Therapeutics (NYSE: ADCT) is driving the advancement of antibody drug conjugate technology. The company is enriching the treatment protocols for patients battling both hematologic malignancies and solid tumors. Through pioneering therapies like ZYNLONTA and multiple standalone clinical projects, ADC Therapeutics is committed to transforming the healthcare experience through innovative treatments.

With solid foundations and a clear vision, ADC Therapeutics is positioned not only to thrive but also to set new benchmarks in cancer treatment innovation.

Frequently Asked Questions

What is the purpose of the $60 million PIPE financing?

The funding aims to support the commercial expansion of ZYNLONTA, strengthen the company’s financial position, and cover general operational needs.

Who led the PIPE financing for ADC Therapeutics?

The PIPE is led by TCGX, with participation from Redmile Group and other institutional investors.

When is the PIPE financing expected to close?

The anticipated closure is projected for a date in the near future, subject to customary closing conditions.

What is ZYNLONTA?

ZYNLONTA is a CD19-directed antibody drug conjugate designed to treat adult patients with relapsed or refractory large B-cell lymphoma.

What are ADC Therapeutics' future goals?

ADC Therapeutics aims to enhance its commercial growth trajectory and fund additional research into innovative therapies leveraging its proprietary ADC technology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 0

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 91

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 110

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 21

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 31

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 70

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 163

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 135

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 0

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 76

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring SpaceX's Possible IPO and Its Strategic Implications

Updated Category News Views 194

SpaceX's Strategic Inflection Point SpaceX is signaling preparation for a potential public offering, marking a significant change for one of the most important private companies in the aerospace industry. Although Chief Financial Officer Bret Johnsen has not confirmed an IPO, the message shifts the conversation from mere speculation to a focus on conditional execution....

Continue Reading
Exploring Intel's Options Trading Dynamics and Market Insights

Updated Category News Views 107

Understanding Recent Trends in Intel's Options Market In recent times, significant investors, often referred to as 'whales', have shown a distinct bearish outlook on Intel. Their actions reflect a deeper narrative surrounding the stock and offer a glimpse into market sentiments. Upon analyzing the trading history for Intel (NASDAQ: INTC), we uncovered 31 trades that...

Continue Reading
Surging Growth in the Wasabi Market Driven by Health Benefits

Updated Category News Views 271

Exploring the Growth of the Wasabi Market As consumers become increasingly aware of the numerous health benefits associated with wasabi, the demand for this spicy condiment is on the rise. From 2025 to 2029, the global wasabi market is anticipated to grow by USD 422.2 million, reflecting a remarkable compound annual growth rate (CAGR) of 9.9%. This growth is largely...

Continue Reading
Abel Noser Solutions' Innovative Tool Recognized at Awards

Updated Category News Views 276

Abel Noser Solutions Wins Best Buy-Side TCA Tool Trading Technologies International, Inc. (TT), a leader in capital markets technology, recently announced a remarkable achievement: Abel Noser Solutions has earned the coveted title of Best Buy-Side TCA (Transaction Cost Analysis) Tool in the esteemed Buy-Side Technology Awards 2024. This recognition highlights Abel Noser's...

Continue Reading
Intuitive's Q1 Financial Highlights Show Strong Growth in Revenue

Updated Category News Views 237

Intuitive Surgical Reports Strong First Quarter Financial Performance Intuitive Surgical, a global innovator in robot-assisted surgery, has just unveiled its impressive financial results for the quarter ending March 31, 2025. The company's steady rise in revenue showcases its commitment to improving patient care through advanced technology. Key Highlights from Q1 Results...

Continue Reading